Premium
Corrective use of the 2.5‐mm GFX stent for suboptimal angioplasty results in small coronary arteries
Author(s) -
Eeckhout Eric,
Grobéty Michel,
Vogt Pierre,
Stauffer JeanChristophe,
Roguelov Hristan,
Urban Philippe,
Goy JeanJacques
Publication year - 1999
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/(sici)1522-726x(199910)48:2<157::aid-ccd7>3.0.co;2-s
Subject(s) - medicine , stent , myocardial infarction , percutaneous coronary intervention , stenosis , angioplasty , coronary artery disease , cardiology , percutaneous , revascularization , thrombosis , coronary arteries , surgery , radiology , artery
To evaluate the clinical efficacy of endoluminal stenting in the setting of percutaneous intervention for small coronary artery lesions, we reviewed our results on stenting with the 2.5‐mm GFX stent (Arterial Vascular Engineering, Santa Rosa, CA) during an 18‐month study period. A total of 120 patients with significant coronary artery disease in vessels ≤2.6 mm were followed up clinically. Procedural success (defined as angiographic residual stenosis <20% without clinical complications) was obtained in 94% of cases. In‐hospital complications were death (1%), non–Q‐wave myocardial infarction (5%), and urgent repeat percutaneous intervention because of stent thrombosis (3%). During a mean follow‐up of 9.8 months (range, 6–23 months), the following complications were noted: myocardial infarction (1%), clinical need for repeat intervention (13%) requiring repeat percutaneous treatment (12%) and surgical revascularization (1%). In conclusion, transcatheter application of a specifically designed stent for coronary artery disease in small vessels seems safe and efficient with a low incidence of adverse events during follow‐up. Cathet. Cardiovasc. Intervent. 48:157–161, 1999. © 1999 Wiley‐Liss, Inc.